About Opal

For further information on Opal BioSciences, please contact us or review our investor relations documentation here.

Kenneth Windle

Kenneth Windle

Chairman, Non-Executive Director | BPharm, DipEc, MPS

Ken Windle worked 30 years with Glaxo/Glaxo Wellcome (now gsk) in International positions including Member of the Group’s Executive Committee. This career in-cluded Head of Global Commercialisation based in London, CEO of subsidiaries in UK, Australia, and Regional President Asia Pacific. He was Chairman and CEO of Advent Pharmaceuticals Pty Ltd which he co-founded in 2001 and sold in2018. He was Director of Aus Bio Ltd, Chairman of their R&D Committee, Deputy Chair of Acrux, and NED of NZ Pharmaceuticals. He is Chairman of RMIT’s PAC and NED of Opal. He served 8 years as a Member of Innovation Australia which included Chairman of the Board’s COMET and P3 Committees, member of IIIF Committee, and PISG Working Group. He was Chairman of the working group in Victorian Govt’s. Biotechnology Strategic Development Plan. Graduating from Otago Uni-versity in Pharmacy and pharmacology, he further studied Economics at Massey University, and completed the Executive Programme at London Business School. Mr Windle has previously served as Consultant to the (Australian) Prime Minister's Science Council on Industry Development, Director of the (Singapore) Economic Development Board EDB, and (Singapore’s) Committee on Competitiveness. He was for 2 three year terms Chairman of the APMA (now Medicines Australia), a member of the Pharmaceuticals Industry Advisory Committee, a member of Phar-maceuticals Industry Action Agenda (PIAAG), member of the Pharmaceuticals In-dustry Strategy Group (PISG), and has been twice a winner of the Governor of Victoria’s Export Prize.

Julie Phillips

Julie Phillips

Managing Director | BPharm, DHP, MSc, MBA

Ms Julie Phillips has a strong background in the biotech and pharmaceutical in-dustry, having worked as the CEO and Director of start-up Australian biotechnolo-gy companies operating in the life sciences sector. She is Managing Director of BioDiem's subsidiary, Opal Biosciences Ltd, Chairman of the Innovation and Sci-ence Australia’s R&D Incentives Committee, until Feb 2020 was Chairman of AusBiotech Ltd, the peak biotechnology industry association in Australia, and is currently a Director of the Medtech and Pharma Growth Centre, MTP Connect. Julie has also been appointed to the University of Newcastle's Council and sits on a number of government advisory committees.

Hugh M Morgan AC

Hugh M Morgan AC

Non-Executive Director | LLB, BCom

Hugh Morgan is Principal of First Charnock Pty Ltd. Hugh was appointed Chief Executive Officer of Western Mining Corporation (1990-2003) and prior to that served as an Executive Officer (1976-1986) and then Managing Director (from June 1986). Hugh has served as a Director of Alcoa of Australia Limited (1977-1998 and 2002-2003); Director of Alcoa Inc. (1998-2001); Member of the Board of the Reserve Bank of Australia (1981-1984 and 1996-2007); President of the Australian Japan Business Co-Operation Committee (1999-2006); Joint Chair of the Commonwealth Business Council (2003-2005) and now Emeritus Director; President of the Business Council of Australia (2003-2005) and now an Honorary Member; Member of the Anglo American plc Australian Advisory Board (2006-2014). Hugh was a Member of the Lafarge International Advisory Board; is Chairman of the Order of Australia Association Foundation Limited; Trustee Emeritus of The Asia Society New York; Chairman Emeritus of the Asia Society AustralAsia Centre; Member of the Asia Society Australia Advisory Council; President of the National Gallery of Victoria Foundation. Hugh is a graduate in Law and Commerce from the University of Melbourne.University of Melbourne.

Peter Snowball

Peter Snowball

Non-Executive Director

Peter’s successful career in the financial markets started at Barclays Bank and then the London Futures Exchange. After emigrating to Australia in 1971 he traded on the Sydney Wool Futures Exchange for global clients. Then back in London for a short time Peter became a senior broker at Shearson Lehmann Brothers with his own client base of professional traders, trading mainly financial futures in Chicago. Later in Australia Peter set up a financial futures broking desk at Merrill Lynch in Sydney and subsequently at FIMAT Australia, broking interest rate futures into Singapore and Chicago. Peter moved to J B Were in 1994 where he switched to broking equities for retail clients and within five years became one of the biggest business writers in the Sydney office and in the Company. After a short time supporting the Philanthropic Services team, Peter left J B Were in 2014 and moved to roles with smaller private companies assisting in company turn-arounds and corporate transactions. Peter was the chairman of Philip Shaw Wines Pty Ltd until December 2019.

Find us at the office

Opal Biosciences Ltd
Level 4, 100 Albert Road
South Melbourne
Victoria 3205
Australia

Opal Biosciences Ltd

ACN 605 631 963

Telephone: + 61 3 9692 7240
Facsimile: + 61 3 9077 9233

Twitter: @Opalbiosciences

Contact Us